Search results for "vaccines"

showing 10 items of 554 documents

Immunogenicity and reactogenicity of HbOC vaccine administered simultaneously with acellular pertussis vaccine (DTaP) into either arms or thighs of i…

1997

To evaluate the reactogenicity and immunogenicity of a Haemophilus influenzae type b conjugate vaccine (HbOC) and of a tricomponent acellular pertussis vaccine (DTaP) when injected simultaneously into either contralateral arms or into contralateral thighs, 110 infants were enrolled to receive three doses of DTaP at 3, 4, and 5 months and two HbOC doses at 3 and 5 months of age. Administration of either of the two vaccines into arms was associated with significantly more local side effects than administration into thighs. There was no difference in geometric mean concentration (GMC) values for any of the four vaccine antigens between subjects who had been vaccinated into arms or thighs. Afte…

Microbiology (medical)MaleConjugate vaccinemedicineHumansWhooping coughBacterial CapsulesHaemophilus VaccinesPertussis VaccineReactogenicityVaccines Conjugatebusiness.industryTetanusDiphtheriaImmunogenicityPolysaccharides BacterialToxoidInfantGeneral Medicinemedicine.diseaseAntibodies BacterialVaccinationInfectious DiseasesImmunologyFemalebusinessInfection
researchProduct

Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

2006

Combination vaccines against common childhood diseases are widely used, provide an improved coverage, are more convenient and are more cost-effective than multiple injections. We conducted a study to evaluate the safety and immunogenicity of a combined measles-mumps-rubella-varicella (MMRV) candidate vaccine in comparison with the separate administration of licensed measles-mumps-rubella (MMR; Priorix) and varicella (V; Varilrix) vaccines.Healthy children 12-18 months of age received 2 doses of MMRV vaccine (3 lots) 6-8 weeks apart (MMRV group) or 1 dose of MMR vaccine administered concomitantly with 1 dose of varicella vaccine, followed by a second dose of MMR at 6-8 weeks later (MMR+V gro…

Microbiology (medical)MaleHerpesvirus 3 HumanFeverPainHyperemiamedicine.vaccineAntibodies ViralRubellaMeaslesCombination vaccinesChickenpox VaccinemedicineHumansVaccines CombinedMeasles mumps rubella varicellaMMRV vaccinebusiness.industryImmunogenicityvirus diseasesInfantmedicine.diseaseInfectious DiseasesMumps virusMeasles virusImmunoglobulin GPediatrics Perinatology and Child HealthImmunologyFemaleViral diseasebusinessMeasles-Mumps-Rubella VaccineThe Pediatric infectious disease journal
researchProduct

Disease Burden of Rotavirus Gastroenteritis in Children Residing in Germany: A Retrospective, Hospital-based Surveillance.

2015

Background Representative, population-based epidemiologic data for gastroenteritis caused by rotavirus (RV) are rare. RV vaccines were first licensed in Europe in 2006 and recommended in 5 western federal states in 2008 or thereafter. This study establishes a baseline for assessing the impact of vaccination and delineates the RV disease burden in Germany today. Methods Nationwide data obtained from hospitals for children 0 to 10 years of age and transferred to the Federal Statistical Office were analyzed retrospectively. Acute gastroenteritis cases because of RV were identified by the International Classification of Diseases code (ICD-10) combined with the referring diagnosis-related group …

Microbiology (medical)MaleRotavirusPediatricsmedicine.medical_specialtyPopulationmedicine.disease_causeRotavirus Infections03 medical and health sciencessymbols.namesake0302 clinical medicinePublic health surveillanceCost of Illness030225 pediatricsRotavirusGermanymedicineOdds RatioHumansPublic Health Surveillance030212 general & internal medicinePoisson regressionGeography MedicaleducationChildDisease burdenRetrospective Studieseducation.field_of_studybusiness.industryInfant NewbornRotavirus VaccinesInfantRetrospective cohort studyOdds ratioGastroenteritisVaccinationHospitalizationInfectious DiseasesChild PreschoolPediatrics Perinatology and Child HealthsymbolsFemalebusinessThe Pediatric infectious disease journal
researchProduct

Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated …

2009

ABSTRACT We report on the efficacy of the genetically engineered Candida albicans tet-NRG1 strain as an experimental live, attenuated vaccine against disseminated candidiasis in both immunocompetent and immunodeficient mice mostly dependent on T-cell immunity. This experimental vaccination model may represent an important tool to unravel the mechanisms of protective immunity during candidiasis.

Microbiology (medical)Neuregulin-1T-LymphocytesClinical BiochemistryImmunologyBiologyVaccines AttenuatedMicrobiologyMiceImmunityCandida albicansImmunology and AllergyAnimalsCandida albicansFungal vaccineVaccines SyntheticAttenuated vaccineStrain (biology)Candidiasisbiochemical phenomena metabolism and nutritionDisseminated Candidiasisbiology.organism_classificationVaccine ResearchVirologySurvival AnalysisVaccinationImmunizationFungal VaccinesClinical and vaccine immunology : CVI
researchProduct

Four and One-Half-Year Follow-up of the Effectiveness of Diphtheria-Tetanus Toxoids-Acellular Pertussis/Haemophilus influenzae Type b and Diphtheria-…

2004

Background: Recently an increase in the number of invasive Haemophilus influenzae type b (Hib) cases was observed in the United Kingdom, which coincided with a temporary change from diphtheria-tetanus toxoids-wild-type pertussis to diphtheria-tetanus toxoids-acellular pertussis (DTaP) Hib vaccines. A study in Germany based on approximately 2 years of follow-up, estimated vaccine effectiveness (VE) of DTaP/Hib and DTaP-inactivated poliovirus/Hib combination vaccines against invasive Hib disease to be high. Objectives: To assess VE of DTaP-containing Hib vaccines against Hib in Germany with the use of extended follow-up of case surveillance and vaccine uptake. Subjects and Methods: Cases with…

Microbiology (medical)Pediatricsmedicine.medical_specialtyHaemophilus InfectionsBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinesmedicine.disease_causecomplex mixturesHaemophilus influenzaeCohort StudiesGermanymedicineHumansVaccines CombinedWhooping coughHaemophilus VaccinesRetrospective Studiesbusiness.industryTetanusDiphtheriaPoliovirusHaemophilus influenzae type bToxoidInfantbacterial infections and mycosesmedicine.diseaseVirologyPoliovirus VaccinesInfectious DiseasesCase-Control StudiesChild PreschoolPediatrics Perinatology and Child HealthEnterovirusbusinessPediatric Infectious Disease Journal
researchProduct

Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influe…

2001

Background. Since 1996 in Germany primary infant immunization against Haemophilus influenzae has been most commonly given in the form of diphtheria-tetanus toxoids-acellular pertussis/H. influenzae type b (DTaP/Hib) or diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b (DTaP-IPV/Hib) combination vaccines. These combination vaccines elicit lower anti-Hib antibody concentrations than the equivalent Hib conjugate administered as a separate injection, but the clinical relevance of this phenomenon is unknown. Methods and findings. To assess the impact of DTaP/Hib combination vaccines on the incidence of invasive Hib disease in Germany, two independent s…

Microbiology (medical)Pediatricsmedicine.medical_specialtyHaemophilus Infectionsmedicine.disease_causeDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesHaemophilus influenzaeGermanymedicineHumansVaccines CombinedWhooping coughImmunization ScheduleHaemophilus Vaccinesbusiness.industryTetanusDiphtheriaIncidenceVaccinationToxoidHaemophilus influenzae type bInfantmedicine.diseaseAntibodies BacterialVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesImmunizationChild PreschoolPediatrics Perinatology and Child HealthImmunologybusinessMeningitisSentinel SurveillanceThe Pediatric infectious disease journal
researchProduct

Type-Specific Antibodies to Pneumococcal Capsular Polysaccharide Acquired either Naturally or after Vaccination with Prevenar in Children with Underl…

2006

ABSTRACT The antibody response to capsular polysaccharides of pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F elicited either naturally or after vaccination with Prevenar was investigated in a cohort of children ( n = 163) with underlying chronic or recurrent lung diseases at risk of developing pneumococcal pneumonia and ultimately invasive disease. Serum concentrations of serotype-specific antibodies, as measured by enzyme-linked immunosorbent assay, in unvaccinated children ( n = 88) were higher in nasopharyngeal carriers ( n = 10) than in noncarriers ( n = 78) both at baseline and during follow-up. However, the antibody levels depended on the serotype and age of the children. Dur…

Microbiology (medical)SerotypeLung DiseasesMaleHeptavalent Pneumococcal Conjugate VaccineAdolescentClinical BiochemistryImmunologyEnzyme-Linked Immunosorbent AssayMeningococcal VaccinesMeningococcal vaccineStatistics NonparametricPneumococcal VaccinesAntibody SpecificitymedicineImmunology and AllergyHumansChildLungbiologybusiness.industryPolysaccharides BacterialVaccinationAntibody titerInfantmedicine.diseaseVaccine ResearchAntibodies BacterialVaccinationmedicine.anatomical_structureChild PreschoolCohortPneumococcal pneumoniaImmunologyChronic Diseasebiology.proteinFemaleAntibodybusinessFollow-Up Studies
researchProduct

Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease.

2016

Summary Objectives The treatment of inflammatory bowel disease (IBD) has been revolutionized by the use of immunomodulatory agents. Although these potent drugs are effective in controlling disease activity, they also cause an increased risk of new infections or reactivation of latent infections. On these premises, we aimed to provide guidance on the definitions of immunocompromised patients, opportunistic infections and the risk factors associated with their occurrence in an IBD context, and to suggest the proper screening tests for infectious diseases and the vaccination schedules to perform before and/or during therapy with immunomodulators. Methods All the most recent evidences – filtere…

Microbiology (medical)medicine.medical_specialtyBiologicSettore MED/17 - Malattie InfettiveScreening testOpportunistic InfectionDiseaseOpportunistic InfectionsInflammatory bowel diseaseImmunosuppressive Agent03 medical and health sciencesImmunocompromised Host0302 clinical medicinemedicineHumansIn patient030212 general & internal medicineIntensive care medicineImmunosuppressantCrohn's diseaseVaccinesUlcerative colitibusiness.industryInflammatory Bowel Diseasemedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisVaccinationCrohn's diseaseInfectious DiseasesInfectious disease (medical specialty)Immunology030211 gastroenterology & hepatologybusinessVaccineImmunosuppressive AgentsHumanThe Journal of infection
researchProduct

Cost-Effectiveness of Pneumococcal Vaccination of Older People: A Study in 5 Western European Countries

1999

Pneumococcal vaccination of older persons is thought to be cost-effective in preventing pneumococcal pneumonia, but evidence of clinical protection is uncertain. Because there is better evidence of vaccination effectiveness against invasive pneumococcal disease, we determined the cost-effectiveness of pneumococcal vaccination of persons agedor =65 years in preventing hospital admission for both invasive pneumococcal disease and pneumococcal pneumonia in 5 western European countries. In the base case analyses, the cost-effectiveness ratios for preventing invasive disease varied from approximately 11,000 to approximately 33,000 European currency units (ecu) per quality-adjusted life year (QAL…

Microbiology (medical)medicine.medical_specialtyPediatricsCost effectivenessCost-Benefit AnalysisPneumococcal VaccinesmedicineHumansAgedAged 80 and overbusiness.industryIncidenceMortality rateIncidence (epidemiology)VaccinationPneumonia Pneumococcalmedicine.diseaseQuality-adjusted life yearSurgeryEuropeVaccinationPneumoniaInfectious DiseasesPneumococcal vaccinePneumococcal pneumoniaQuality-Adjusted Life YearsbusinessClinical Infectious Diseases
researchProduct

HBV core particles as a carrier for B cell/T cell epitopes.

2001

In the middle 80s, recombinant hepatitis B virus cores (HBc) gave onset to icosahedral virus-like particles (VLPs) as a basic class of non-infectious carriers of foreign immunological epitopes. The recombinant HBc particles were used to display immunodominant epitopes of hepatitis B, C, and E virus, human rhinovirus, papillomavirus, hantavirus, and influenza virus, human and simian immunodeficiency virus, bovine and feline leukemia virus, foot-and-mouth disease virus, murine cytomegalovirus and poliovirus, and other virus proteins, as well as of some bacterial and protozoan protein epitopes. Practical applicability of the HBc particles as carriers was enabled by their ability to high level …

Models MolecularAntigenicityHepatitis B virusvirusesMolecular Sequence DataMolecular ConformationEpitopes T-LymphocyteBiologymedicine.disease_causeFeline leukemia virusVirusEpitopeAntigenVirologymedicineAnimalsHumansAmino Acid SequenceAntigens ViralHepatitis B virusVaccines SyntheticPoliovirusViral Core Proteinsvirus diseasesViral VaccinesGenetic TherapySimian immunodeficiency virusbiology.organism_classificationVirologyMolecular biologyInfectious DiseasesEpitopes B-LymphocyteIntervirology
researchProduct